Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Publisher Correction: The hothouse for protein design

The Original Article was published on 23 June 2020

Correction to: Nature Biotechnology https://doi.org/10.1038/s41587-020-0586-0, published online 23 June 2020.

In the version of this article initially published, a merger between Neoleukin Therapeutics and Aquinox Pharmaceuticals was described as an acquisition of the former by the latter. Specifically, the last sentence of section “Eliminating side effects” originally read “That August, the company was purchased by Vancouver-based Aquinox Pharmaceuticals, in a deal worth around $40 million.” It has been changed to “That August, the company merged with Vancouver-based Aquinox Pharmaceuticals to become a publicly traded entity, the first IPD spinout to go public, under the name Neoleukin Therapeutics.” The error has been corrected in the HTML and PDF versions of the article.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Caroline Seydel.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Seydel, C. Publisher Correction: The hothouse for protein design. Nat Biotechnol 38, 1001 (2020). https://doi.org/10.1038/s41587-020-0641-x

Download citation

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing